Date: 2015-06-22
Type of information: Nomination
Compound:
Company: Ultragenyx Pharmaceutical (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 22, 2015, Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced it has appointed Jayson Dallas, M.D., as its Chief Commercial Officer, effective August 3, 2015. In this newly created role, Dr. Dallas will be responsible for building and leading an innovative global organization required for the successful commercialization of the company\'s products. He will be responsible for the overall commercial operations, including sales, marketing, reimbursement, and new product planning. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx\'s CEO, and will serve on the Executive Leadership Team. Dr. Dallas most recently served as General Manager of Roche in the United Kingdom. Prior to this, at Genentech he held two different positions as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology. Prior to joining Genentech, Dr. Dallas worked at Novartis and Pharmacia in the US and previously at Roche in Switzerland. Over the course of his 21 year career in the industry, Dr. Dallas has successfully overseen multiple product launches, internationally and in the US, and has led numerous commercial organizations through periods of rapid growth. Earlier in his career, Dr. Dallas worked in various medical functions within the industry and also as a practicing clinician. Dr. Dallas holds an MD from the University of the Witwatersrand, Johannesburg, South Africa and an MBA from Ashridge Business School in the UK.
Financial terms:
Latest news:
